Newsletters

[Gut] Researchers constructed a diagnostic model for chronic pancreatitis (CP) and depicted molecular landscape of CP based on extracellular vesicle long RNA.

[Nature Communications] Scientists investigated the effect of Amuc_1098 on acute pancreatitis in mice induced by caerulein combined with lipopolysaccharide or L-arginine.

[iScience] Investigators conducted a phosphoproteomics analysis to evaluate phosphorylation levels, and administered extracellular vesicles derived from human adipose mesenchymal stem cells in a mouse model of severe acute pancreatitis and assessed their impact on Treg differentiation.

[Molecular Cancer] The authors investigated the mechanisms underlying the interaction and influence between microvascular invasion, which contributes to metastasis and poor prognosis of PDAC, and the tumor microenvironment.

[Journal for Immunotherapy of Cancer] Researchers demonstrated that relaxin can enhance intratumoral accumulation of programmed death-ligand 1-targeted RIT (lutetium-177-labeled atezolizumab) in a multifaceted manner to elicit synergistic antitumor immune response against desmoplastic and poorly immunogenic pancreatic tumors.

[Cell Death & Disease] Scientists utilized molecular cytology techniques, animal models, and human pancreatic cancer tissues to investigate the role of FoxM1 in Smad4 stabilization and its regulation of TGF-β signaling.

[Cancer & Metabolism] Investigators suggested that SRRM1 may serve as a predictive biomarker for gemcitabine (GEM) response in pancreatic cancer. Targeting SRRM1 in conjunction with ferroptosis inducers could offer a promising strategy to overcome GEM resistance.

[Tissue Barriers] Researchers performed an integrative analysis of 177 RNA-Seq datasets from TCGA and GTEx to characterize Claudin family alterations in PDAC.

[Gene] The authors summarize current knowledge on the multifaceted roles of ncRNAs across major cellular compartments of the tumor microenvironment, highlight key barriers that limit their diagnostic and therapeutic potential, and discuss emerging strategies that may accelerate the development of ncRNA-guided precision medicine in PDAC.

[BridgeBio Oncology Therapeutics, Inc.] BridgeBio Oncology Therapeutics, Inc. announced that the US FDA has granted Fast Track designation to BBO-11818 for the treatment of adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma.

[AlzeCure Pharma AB] AlzeCure Pharma AB announced that the last patient’s last visit has now occurred in the ongoing Phase Ib clinical trial of ACD856, the lead drug candidate within the NeuroRestore platform, which is being developed for Alzheimer’s disease and other indications.

[Rhody Today] The University of Rhode Island (URI)’s Interdisciplinary Neuroscience Program highlighted student research in a variety of neuroscience specialties at the fourth annual URI Neuroscience Symposium. Students researched such topics as mitochondrial dysfunction and drug-loaded nanoparticles with the ability to penetrate the blood-brain barrier.